

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Liu et al.

Atty. Docket: PRD2203USPCT

Serial No.:

10/594,832

Art Unit:

1654

Filed:

July 16, 2007

Examiner:

Abdel A. Mohamed

For:

PROKINETICIN 2BETA

Confirmation No.: 8383

PEPTIDE AND ITS USE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(c)(2) and the Commissioner is requested to charge Deposit Account No. 10-0750 for the \$180.00 fee set forth in 37 C.F.R. § 1.17(p). If any other fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.

Copies of foreign patent documents and non-patent references only are enclosed in accordance with 37 CFR 1.98 (a)(2). The U.S. patents and U.S. patent application publications listed on the attached Form PTO-1449 are not enclosed.

Each cited reference is in the English language.

02/11/2009 MBELETE1 00000051 100750

10594832

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that any of the cited references qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the Form PTO-1449 to confirm consideration of each reference.

Respectfully submitted,

Date: February 6, 2009

Linda S. Evans Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7093

(858) 320-3406





icate of Mailing:

undersigned certifies that this correspondence is being sent via first-class mail, with sufficient postage, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

this 6th day of February, 2009.

Helen J. Glenister

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Liu et al.

Atty. Docket: PRD2203USPCT

Serial No.:

10/594,832

Art Unit:

1654

Filed:

July 16, 2007

Examiner:

Abdel A. Mohamed

For:

PROKINETICIN 2BETA!

PEPTIDE AND ITS USE

Confirmation No.: 8383

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(c)(2) and the Commissioner is requested to charge Deposit Account No. 10-0750 for the \$180.00 fee set forth in 37 C.F.R. § 1.17(p). If any other fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.

Copies of foreign patent documents and non-patent references only are enclosed in accordance with 37 CFR 1.98 (a)(2). The U.S. patents and U.S. patent application publications listed on the attached Form PTO-1449 are not enclosed.

Each cited reference is in the English language.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that any of the cited references qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the Form PTO-1449 to confirm consideration of each reference.

Respectfully submitted,

Date: February 6, 2009

Linda S. Evans Reg. No. 33,873

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933-7003 (858) 320-3406